FTH
Faeth Therapeutics, Inc.
24.90$
-7.3%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | +24.5% | +11.5% | +141.9% | +36.2% | -1.8% | +2.5% | +4.0% | +4.7% | -7.3% | -70.3% | +1.5% | -1.5% | +3.7% | -0.7% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -9.5% | +63.8% | -0.6% | -28.5% | +31.7% | +75.3% | +9.2% | -7.6% | +25.2% | -14.2% | +43.8% | -43.4% | -13.8% | -14.9% | +17.7% | +9.4% | -6.8% | +1.2% | -3.2% | -17.0% | -32.0% | +0.1% | -14.6% | +729.0% | -48.9% | – | |
| – | +94.3% | – | – | +41.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -24.7% | -13.4% | +20.6% | +606.3% | -53.3% | – | |
| – | +20.4% | +18.3% | +10.5% | -5.4% | +55.0% | +22.8% | +5.4% | -10.8% | +32.5% | -14.7% | +31.3% | -18.4% | -11.9% | -24.9% | +10.0% | +7.3% | -11.0% | +0.4% | -6.5% | +1.3% | -28.4% | -6.8% | +2.2% | +659.9% | -51.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +16.7% | -99.8% | +0.0% | +1,700.0% | -94.4% | +4,800.0% | +45.6% | +43.0% | -20.6% | -29.2% | -94.2% | +320.0% | -9.5% | -13.2% | -6.1% | -9.7% | -14.3% | -12.5% | -19.0% | -23.5% | -23.1% | -40.0% | -50.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.